OrthoPediatrics posts Street-beating Q1 results

OrthoPediatrics (Nasdaq:KIDS) this week posted first-quarter results that beat the overall consensus on Wall Street.

The Warsaw, Indiana-based company reported losses of $9.1 million, or -47¢ per share, on sales of $23.4 million for the three months ended March 31, for a bottom-line gain of 12.3% on sales growth of 9.11% compared with Q1 2021.

Adjusted to exclude one-time items, earnings per share were -30¢, 7¢ ahead of The Street, where analysts were looking for sales of $22.75 million.

“I am extremely proud of our team and what they were able to accomplish to start the year strong despite the impact of Omicron in January and February,” President and CEO David Bailey said in a news release. We announced a limited launch of our new PediFlex Advanced Interlocking Clamp, received an additional FDA clearance for Drive Rail, our external fixation system and also made significant progress on multiple R&D projects. Additionally, our recent acqu…

Read more
  • 0

OrthoPediatrics acquires MD Orthopaedics and its clubfoot bracing technology

OrthoPediatrics (Nasdaq:KIDS) today announced that it is acquiring MD Orthopaedics in a transaction valued up to $19.6 million.

The Warsaw, Indiana-based will acquire MD Orthopedics and its bracing product lines and Mitchell Ponseti ankle-foot orthosis system to treat clubfoot. Under terms of the agreement, OrthoPediatrics buy the Wayland, Iowa-based company for an upfront cash payment of $8.2 million and $8.9 million in company stock with an additional $2.5 million in restricted stock which vest after three years.

MD Orthopaedics is a privately-held company that develops and commercializes custom fit bracing systems that support the gold standard treatment for clubfoot known as the Ponseti Technique. It will be integrated into OrthoPediatrics’ trauma and deformity business and will continue to focus on the treatment of clubfoot.

OrthoPediatrics plans to grow the MD Orthopaedics product offerings and develop new technology that addresses other unme…

Read more
  • 0

OrthoPediatrics reports mixed-bag results in Q3

OrthoPediatrics (NSDQ:KIDS) this week posted third-quarter results that beat the earnings consensus on Wall Street but missed revenue estimates.

The Warsaw, Indiana-based orthopedics company reported losses of -$2.2 million, or -11¢ per share, on sales of $25.1 million for the three months ended Sept. 30, for a sales growth of 12.94% compared with Q3 2020.

Adjusted to exclude one-time items, earnings per share were -15¢, 13¢ ahead of The Street, where analysts were looking for sales of $26.28 million.

“We are proud to report double-digit growth despite the temporary impact of COVID, RSV, and hospital staffing shortages. International growth was particularly strong indicating continued recovery of these markets. We continue to make substantive progress in advancing our key strategic initiatives, including securing enabling technologies and sponsoring multiple key clinical education events,” president and CEO David Bailey said in a news release.

Read more
  • 0

OrthoPedatrics launches neuromuscular scoliosis system

OrthoPediatrics (NSDQ:KIDS) today said it launched its Response neuromuscular scoliosis system.

The Warsaw, Ind.–based company designed the system to treat pediatric patients who have neuromuscular scoliosis. It has a complete set of implants and instruments to simplify insertion and has specific options to address extreme hyperlordosis and sacral/pelvic fixation.

“Neuromuscular scoliosis patients can present with a wide array of extreme 3-dimensional deformities, which can require highly individualized and complicated surgical treatment. The addition of the neuromuscular scoliosis system to the OrthoPediatrics Response offering was designed to improve the speed and efficacy of the instrumentation, correction and stabilization of these complicated deformities, with the aim of optimizing outcomes. This now makes the OP Response system the ideal one for all types of pediatric spinal deformity,” Scott Luhmann, pediatric orthopedic surgeon and chief of …

Read more
  • 0

OrthoPediatrics ticks up on Street-beating Q1 results

OrthoPediatrics (NSDQ:KIDS) yesterday posted first-quarter results that beat the overall consensus on Wall Street and increased its full-year guidance.

The Warsaw, Ind.-based company reported losses of -$10.4 million, or -54¢ per share, on sales of $21.5 million, for the three months ended March 31, for a sales growth of 31.2% compared with Q1 2020.

Adjusted to exclude one-time items, earnings per share were -25¢, 2¢ ahead of The Street, where analysts were looking for sales of $19.86 million.

“The company’s first-quarter results reflect the resilience of our business, steady execution of our strategy and the unwavering dedication of our team. With revenue growth exceeding 30% year-over-year, adjusted EBITDA and gross margins continuing to improve, and meaningful progress across all product categories, OrthoPediatrics is well-positioned for sustained growth as we advance toward recovery from the COVID-19 pandemic. We are particularly encouraged by the 19…

Read more
  • 0

9 medical devices you should keep an eye out for in 2021

The medical device industry weathered the COVID-19 pandemic well — and is now set to roll out a host of innovations in 2021.

Economists generally expect the U.S. to see a boom as we emerge from the pandemic and resulting recession. Medtech companies appear set to ride the wave this year, with plans to seek approval or launch a wide range of new products.

Think surgical robotics, smart orthopedic implants, neurostimulation, single-use scopes and much more.

Here are nine devices to especially keep an eye out for this year.

Next>>
Read more
  • 0

OrthoPediatrics misses earnings, revenue consensus in Q4

OrthoPediatrics (NSDQ:KIDS) posted fourth-quarter results that missed the consensus forecast on Wall Street.

The Warsaw, Ind.-based company reported losses of -$14 million, or -73¢ per share, on sales of $18.9 million for the three months ended Dec. 31, 2020, for a sales loss of -0.15% compared with Q4 2019.

Earnings per share were -73¢ per share, 46¢ behind The Street where analysts were looking for sales of $20.5 million and earnings of -27¢ per diluted share.

“Despite COVID-19, in 2020 we continued the systematic execution of our growth initiatives both domestically and internationally. Elective surgery volumes declined globally but staged a gradual recovery throughout the year. Second-quarter sales declined 25% but then began to recover with third-quarter sales growth of 7% and a 0.1% fourth-quarter sales decline due to the $2.7 million reduction which impacted fourth-quarter revenue growth by 14%,” CEO Mark Throdahl said in a news release.

Read more
  • 0